

**GUFIC BIOSCIENCES LIMITED**

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED / YEAR ENDED 30.06.2016**

Rs. In Lacs

Particulars	Quarter Ended 30.06.2016 Unaudited	Quarter Ended 30.06.2015 Unaudited	For the Year Ended 31.03.2016 Audited	For the Year Ended 31.03.2015 Audited
<b>INCOME:</b>				
Net Sales / Income from Operations (Net of Excise Duty)	5536.25	3759.20	20205.16	15142.61
Other Operating Income	9.12	8.40	26.61	32.53
<b>Total Income from Operations (Net)</b>	<b>5545.37</b>	<b>3767.60</b>	<b>20231.77</b>	<b>15175.14</b>
<b>EXPENSES:</b>				
Cost of Materials Consumed	1542.58	1755.99	7626.31	6579.76
Purchase of Stock-in-Trade	1127.51	557.29	4280.95	1670.77
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(102.88)	(680.64)	(1709.85)	(130.68)
Employee Benefits Expenses	1002.30	745.81	3197.53	1933.33
Depreciation and Amortisation Expenses	91.12	92.36	378.68	385.21
Other Expenses	1338.74	1023.04	4856.12	3675.26
<b>Total Expenses</b>	<b>4999.37</b>	<b>3493.85</b>	<b>18629.74</b>	<b>14113.66</b>
<b>Profit from Operations before Other Income, finance costs and Exceptional Items</b>	<b>546.00</b>	<b>273.75</b>	<b>1602.03</b>	<b>1061.48</b>
Other Income	5.95	1.98	54.24	37.18
<b>Profit from ordinary activities before finance costs and exceptional items</b>	<b>551.95</b>	<b>275.73</b>	<b>1656.27</b>	<b>1098.66</b>
Finance Costs	136.91	114.73	536.84	446.08
<b>Profit from ordinary activities after finance costs but before exceptional items</b>	<b>415.05</b>	<b>161.00</b>	<b>1119.43</b>	<b>652.59</b>
Exceptional Items	0.00	0.00	0.00	0.00
<b>Profit from Ordinary Activities Before Tax</b>	<b>415.05</b>	<b>161.00</b>	<b>1119.43</b>	<b>652.59</b>
Current Tax	185.50	75.00	429.30	278.61
Deferred Tax	(25.71)	(18.03)	(42.63)	(48.84)
Short/(Excess) Tax Provisions of Earlier Years	0.00	0.00	0.34	7.08
<b>Net Profit from Ordinary Activities After Tax</b>	<b>255.26</b>	<b>104.03</b>	<b>732.42</b>	<b>415.74</b>
Extraordinary Items (Net of Tax Expenses)	0.00	0.00	0.00	0.00
<b>Net Profit for the Period</b>	<b>255.26</b>	<b>104.03</b>	<b>732.42</b>	<b>415.74</b>
Paid up Equity Share Capital (Face Value of Rs 1 /- Each)	773.50	773.50	773.50	773.50
Reserves Excluding Revaluation Reserves	2622.31	2040.52	2622.37	1936.49
<b>E.P.S</b>	<b>0.33</b>	<b>0.13</b>	<b>0.95</b>	<b>0.54</b>
<b>Public Shareholding</b>				
-- Number of Shares of Rs 1 /- Each	23222355	23222355	23222355	23222355
-- Percentage of shareholding	30.02%	30.02%	30.02%	30.02%
<b>Promoters and Promoter group Shareholding</b>				
<b>a) Pledged / Encumbered</b>				
-- Number of Shares of Rs 1 /- Each	0	0	0	0
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	0.00%	0.00%	0.00%	0.00%
-- Percentage of Shareholding on total Capital of the company	0.00%	0.00%	0.00%	0.00%
<b>b) Non - Encumbered</b>				
-- Number of Shares of Rs 1 /- Each	54127645	54127645	54127645	54127645
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	100.00%	100.00%	100.00%	100.00%
-- Percentage of Shareholding on total Capital of the company	69.98%	69.98%	69.98%	69.98%

**GUFIC BIOSCIENCES LIMITED**


Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

UNAUDITED SEGMENT WISE RESULTS FOR THE QUARTER / ENDED 30.06.2016				Rs. In Lacs
Particulars	Quarter Ended 30.06.2016 Audited	Quarter Ended 30.06.2015 Unaudited	For the Year Ended 31.03.2016 Audited	For the Year Ended 31.03.2015 Audited
<b>SEGMENT REVENUE</b>				
Sales & Service				
Pharma	5510.15	3650.22	19769.64	13922.95
Consumer	26.10	108.98	435.52	1219.66
<b>Total</b>	<b>5536.25</b>	<b>3759.20</b>	<b>20205.16</b>	<b>15142.61</b>
Unallocabel Income	15.07	10.38	80.85	69.71
<b>Total Segment Revenue</b>	<b>5551.32</b>	<b>3769.58</b>	<b>20286.01</b>	<b>15212.32</b>
<b>SEGMENT RESULTS</b>				
Pharma	1252.15	720.92	4110.06	2701.05
Consumer	2.38	12.04	42.18	136.97
<b>TOTAL</b>	<b>1254.53</b>	<b>732.96</b>	<b>4152.24</b>	<b>2838.02</b>
Less: Unallocated over heads	611.46	364.87	2117.28	1354.15
Finance Charges	136.91	114.73	536.84	446.08
Depreciation	91.12	92.36	378.68	385.21
Tax provision	159.79	56.97	387.01	236.85
<b>Net Profit after Tax</b>	<b>255.26</b>	<b>104.03</b>	<b>732.42</b>	<b>415.74</b>

**Notes forming part of the audited financial results for the quarter ended June 30, 2016**

- The above financial results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors in their meetings held on August 12, 2016.
- For the preparation of these financial results, the company has followed the same accounting policies and generally accepted practices adopted for the preparation of audited financial statements for the year ended March 31, 2016.
- Disclosure about investor complaints: Complaints at the beginning of the period Nil, Received during the period 3; Disposed off during the period: 3, Unresolved as on June 30, 2016: Nil.
- Corresponding previous period figures have been regrouped / rearranged wherever necessary to make them comparable with current period figures.

By Order of the Board  
Gufic Biosciences Limited

  
Pranav J. Choksi  
Chief Executive Officer & Executive Director  
Mumbai dated August 12, 2016